Ferring Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FERRING PHARMS INC, and what generic alternatives to FERRING PHARMS INC drugs are available?
FERRING PHARMS INC has nine approved drugs.
There are twelve US patents protecting FERRING PHARMS INC drugs.
There are one hundred and eighty-four patent family members on FERRING PHARMS INC drugs in thirty-nine countries and fifteen supplementary protection certificates in nine countries.
Summary for Ferring Pharms Inc
International Patents: | 184 |
US Patents: | 12 |
Tradenames: | 9 |
Ingredients: | 4 |
NDAs: | 9 |
Drugs and US Patents for Ferring Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ferring Pharms Inc | MILPROSA | progesterone | SYSTEM;VAGINAL | 201110-001 | Apr 29, 2020 | DISCN | Yes | No | 10,537,584 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Ferring Pharms Inc | DDAVP | desmopressin acetate | INJECTABLE;INJECTION | 018938-002 | Apr 25, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Ferring Pharms Inc | MILPROSA | progesterone | SYSTEM;VAGINAL | 201110-001 | Apr 29, 2020 | DISCN | Yes | No | 10,548,904 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ferring Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ferring Pharms Inc | DDAVP | desmopressin acetate | SOLUTION;NASAL | 017922-001 | Approved Prior to Jan 1, 1982 | 5,763,407 | ⤷ Sign Up |
Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | 10,307,459 | ⤷ Sign Up |
Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | 7,947,654 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FERRING PHARMS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and12 g | ➤ Subscribe | 2019-02-11 |
➤ Subscribe | Oral Solution | 10 mg, 3.5 g, and 12 g | ➤ Subscribe | 2014-05-21 |
International Patents for Ferring Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Slovenia | 3085381 | ⤷ Sign Up |
Lithuania | 3085381 | ⤷ Sign Up |
Eurasian Patent Organization | 201070919 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ferring Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2712622 | LUC00015 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101 |
2782584 | 21C1058 | France | ⤷ Sign Up | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406 |
2782584 | 2021C/558 | Belgium | ⤷ Sign Up | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.